The loss of functional β-2 microglobulin (B2M) expression, which stabilizes the major histocompatibility complex (MHC) class I proteins on the cell surface, leading to decreased tumor cells recognition by CD8+ T cells, was first observed in patients developing resistance to adoptive T cell therapy [48]. Here, CD8A is linked to neoplasm.